OBN Weekly Ophthalmology News Update
Ophthalmology Breaking News
Ophthalmology Breaking News (OBN) is the international source for ophthalmic industry news.
1. FDA Approves ZEISS MEL 90 Excimer Laser for Refractive Surgery
The FDA has granted approval for the ZEISS MEL 90 excimer laser, a cutting-edge device designed for advanced refractive surgery.
The laser features state-of-the-art ablation profiles and enhanced energy stability, providing surgeons with precision tools to improve patient outcomes. The MEL 90’s design enables versatility, allowing treatments for conditions such as myopia, hyperopia, and astigmatism.
This approval paves the way for wider adoption of high-precision refractive surgeries in the U.S., making advanced vision correction technologies more accessible.
2. AbbVie and Regenxbio Share Updates on Gene Therapy ABBV-RGX-314
AbbVie and Regenxbio have announced positive updates on ABBV-RGX-314, their gene therapy candidate for treating wet age-related macular degeneration (AMD) and diabetic retinopathy.
This therapy is administered through a one-time suprachoroidal injection, enabling the body to produce anti-VEGF proteins directly in the eye, potentially reducing the need for frequent injections.
The latest results demonstrate sustained efficacy and safety over a 6-month period, offering a promising alternative for patients requiring long-term management of these conditions.
3. Samsara Reports Positive 6-Month Outcomes for SING IMT Surgery
Samsara Vision has announced positive 6-month outcomes for its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) surgery, a treatment for late-stage age-related macular degeneration (AMD).
The study shows that the device significantly improves central vision while allowing patients to retain peripheral vision, an improvement over earlier-generation implants.
The SING IMT surgery is minimally invasive, making it more accessible and appealing to patients with severe AMD. These results mark a step forward in improving the quality of life for individuals with advanced vision loss.
4. Ocugen Reports Positive 2-Year Results for OCU400 in Gene Therapy
Ocugen has shared promising 2-year data from its clinical trials of OCU400, a gene therapy designed to treat inherited retinal diseases (IRDs) such as retinitis pigmentosa and Leber congenital amaurosis.
The therapy leverages Ocugen’s Modifier Gene Therapy platform, which targets multiple disease-causing mutations simultaneously.
The results indicate sustained improvement in visual function and no significant safety concerns, making OCU400 a strong candidate for further clinical development. If approved, this therapy could provide hope for patients with otherwise untreatable genetic eye conditions.
Stay Updated: For more insights on the latest developments in ophthalmology, visit our website and follow us for regular updates.
Thank you for staying connected with OBN!
Enjoy our LinkedIn updates? You can also stay updated with the latest news via email.
Medico Oculista, Riabilitazione ipovisiva, , Metabolomica, Neuroscienza Applicata nello Sport.
1 个月Sorry, but following the diagnosis, the evolution of the therapeutic approach, and the visual rehabilitation of subjects affected by AMD for about 30 years, it is a fact that the anatomical evolution of the lesion itself determines an instability over time of fixation and its possible further and unpredictable decentration with respect to The fovea. In these cases, representing the majority, is it necessary to remove the implanted telescopic lens and proceed with a new operation?
Optometrist at Vision Express (Essilor Luxottica)
1 个月Insightful